Ibrahim Halil SAHIN, MD @IbrahimSahinMD1 Twitter profile | Pikagi

Pikagi

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2,947

Followers

739

Following

220

Media

2,474

Statuses

Medical Oncologist |NCI Colon Task Force|Clinical trialist-Mentor|Research: Precision Medicine-Immunotherapy-Colorectal CA|EO-CRC| Patient Advocacy|Lead guitar

Pittsburgh, PA

Joined December 2018

Don't wanna be here? Send us removal request.

Pinned Tweet

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️Colorectal cancer is now the leading cause of cancer related death among males aged 20-39 and 40-49 ‼️It was third among 20-39 age group last year. ✳️ Concerning trend is also seen in young women; CRC related death and will likely surpass breast cancer in near future @OncoAlert

Tweet media one

Tweet media two

Tweet media three

Tweet media four

32

377

738

Last Seen Profiles

@imBronxx

@DylHicks

@XavierTates1__

@Staley_Baseball

@Faria_Pti

@stwmaniax

@WheezePlease

@dayoo123456

@charlesgoatt

@jhopeFunds

@sean_scally

@fckhst

@alhydr_almthr

@daxid29

@lulu_ali79

@stwmaniax

@Arwiiita_

@hurricanefstvl

@FortuneOptions

@sitarsubrata

@jonas25uk

@yu_shima_06

@dreams_vista

@Schadenfreux

@patriotsszn6

@wirnteur

@BinorRaja

@kanza_110

@Alby

@benaholtzman

@Toothien

@llmptg

@trrapperellaa

@yui0000129

@bokeplokalmalam

@bokeplokalmalam

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

An important question I receive from my patients is that sugar fuels the cancer and whether if they need to fast or follow a low carb diet❗️This is in fact very important subject particular for patients with GI cancers @oncoalert @CrcChange @manjuggm @fireflyann Here is why 👇

8

47

189

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

I am seeing several young CRC patients at their early 30s and 40s begging for colonoscopy for rectal bleeding/ abdominal pain over SEVERAL months ! 👉We must increase awareness of Early onset CRC among our PCP and GP colleagues‼️ 👉 #EoCRC is an epidemic in the US‼️‼️ @OncoAlert

5

42

141

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#PrayForTurkey My mom and some siblings lives in Gaziantep where the earthquake occurred ! Thankfully they are safe but so many others are still under collapsed buildings! Never felt that helpless … Please pray for Turkey ❗️

Tweet media one

22

9

136

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

11 months

✳️I am thrilled to share that I am appointed to @theNCI Colon Task Force as Alliance Early Career Investigator starting 01/2024❗️ I would like to thank Dr Meyerhardt and Dr @EileenMOReilly for nominating me for this position❗️ @UPMCHillmanCC @PittDeptofMed

21

15

130

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ASCO22 ✳️Happy to say there is great progress for patients with CRC‼️ @OncoAlert @ASCO @manjuggm @CrcChange ‼️ Here is summary of some key studies 👇

5

42

126

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️Our article on neoadjuvant IO for MMR-D/MSI-H colon and rectal cancer is now out ‼️ @JCOOP_ASCO @OncoAlert @ASCO ✳️Happy this came out in #colorectalcancerawareness month ❗️ 👇Here some key points from this article ❗️

Tweet media one

7

42

122

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

My patient with MMR-D rectal cancer now into 3 months of pembrolizumab and achieved complete radiological response by MRI ‼️ ✳️This was one of the most amazing news to share lately with so much joy and emotion ‼️ ✳️IOs do work very well in MMR-D rectal cancer ‼️ @OncoAlert

3

16

114

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️The paper that we discussed the role of neoadjuvant IO therapy for pts with MSI-H colon and rectal cancer is now accepted for publication ❗️ ✳️We reviewed the recent ground breaking progress and elaborated on challenges and future opportunities ❗️ @OncoAlert @JCOOP_ASCO @ASCO

Tweet media one

7

15

111

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

I would like to do my 2nd deep dive post #ASCO22 analysis on #ctDNA guided adjuvant therapy for pts with stage II colon cancer‼️ ✳️The DYNAMIC trial is certainly step forward (kudos) ‼️But doesn’t answer many questions❗️ @OncoAlert @manjuggm @CrcChange @TheColonClub Why ?👇

Tweet media one

3

32

109

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

8 months

✳️It takes a village to make an idea to come to life as an investigator initiated trial but so glad this study will be activated soon with a hope bring new breath to the management of patients with MSI-H CRC‼️ #GI24 @doctorC369 @ronanhsieh @Dr_M_Tejani @AnwaarSaeed3 @ASCO

Tweet media one

3

10

100

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ASCO22 ✳️DYNAMIC trial results are highly exciting and glad to see field is moving forward ! ✳️Very encouraging findings that we are in right pathway to use #ctDNA for adjuvant tx‼️ However there are important points that we need to address 👇 @asco @OncoAlert @MoffittNews

Tweet media one

Tweet media two

Tweet media three

Tweet media four

2

31

97

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️Thrilled to contribute to this work now published by @CancerNetwrk Oncology Journal❗️ ✳️Was amazing to work with Dr. @adasarimd and Dr Lieu and all co-authors ❗️ ✳️Here are some key points from CIRCULATE US trial discussed here 👇 @OncoAlert @manjuggm

Tweet media one

5

30

97

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

An important question I hear from my patients is what vitamins to take while being on chemotherapy‼️ ✳️Perhaps, the question should also be asked as “which vitamins to not to take” while being chemotherapy @oncoalert @CrcChange @fireflyann @manjuggm Here is why👇

5

25

93

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

1 year

✳️A nice article showing tumor mutation burden alone relatively irrelevant for IO response among MSS GI cancers particularly for MSS CRC❗️ Why?👇 @OncoAlert @TheColonClub @TheColonClub @manjuggm @UPMCHillmanCC

2

37

95

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

11 months

✳️Although could not make it to ESMO, here are some my personal comments regarding some of key studies in CRC space ❗️ @OncoAlert @CrcTrialsChat @manjuggm @TheColonClub @colontown 👉 Let’s start with G12C targeting in CRC space ‼️

Tweet media one

1

26

94

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

Thrilled to announce that I will be joining to @UPMCnews - @UPMCHillmanCC ❗️Look forward to excel my research on CRC/EoCRC, contribute its changing treatment paradigm‼️ Also, so excited that our paths are crossing with Dr @teekayowo once again❗️ My mentors @EileenMOReilly , +

15

8

93

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ASCO22 ✳️Our article for ASCO Educational Book is now accepted for publication ❗️ ✳️We have discussed challenges and opportunities of immunotherapy for patient with MSS CRC❗️ ✳️Stay tuned for this highly exciting paper ‼️ @ASCO #ASCOEdBook @OncoAlert

2

11

93

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

9 months

✳️Starting to ASCO GI with a great news ❗️ ✳️ Our paper on the role of Immunotherapy for patients living with MSS CRC is now accepted for publication ‼️ Stay tuned for this exciting article overviewing the literature and unmet needs ‼️ @DenizCanGuven1 @AnwaarSaeed3 @manjuggm

Tweet media one

8

10

92

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

1️⃣ ✳️I would like to dedicate my first tweetorial for Early onset CRC, as I truly believe it is an Epidemic that we know little about it❗️ ✳️CRC is now the leading cause of cancer related death among males among aged 20-49 ❗️ @CrcChange @oncoalert #ColorectalCancerAwarenessMonth

Tweet media one

Tweet media two

3

39

90

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ColorectalCancerAwarenessMonth 1️⃣ ✳️Dedicating my third tweetorial for precision oncology for pts with metastatic CRC❗️ ✳️We have now several actionable genes with novel agents for pts with CRC! Highlights 👇❗️ @manjuggm @colontown @crcchange @thecolonclub @upmchillmancc

6

29

81

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

#GI22 @ASCO @OncoAlert ✳️CtDNA📈 establishes itself as the single most important prognostic factor in CRC after sx ❗️ ✳️Patients with negative CtDNA seems to be doing well without ACT however we need randomized trials to establish this #CIRCULATE -US #COBRA @CrcChange @FightCRC

Tweet media one

Tweet media two

Tweet media three

1

20

77

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️KRAS oncogene, famed as undruggable target, is now potentially actionable particularly G12C mutant ! ✳️How did this perception change? I will go over some recent progress in this tweetorial for KRAS mutant CRC ❗️ @OncoAlert @manjuggm @UPMCHillmanCC 👇

5

21

79

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

Our paper on HER2 targeting for patients with CRC is out‼️ @ASCO @JCOOP_ASCO ✳️In this article we have discussed recent updates and future opportunities @oncoalert Here are some important points discussed👇

Tweet card media

Human Epidermal Growth Factor Receptor 2–Targeting Approaches for Colorectal Cancer: Clinical...

The treatment paradigm for colorectal cancer (CRC) has changed significantly over the past decade with targeted therapeutics. Human epidermal growth factor receptor 2 (HER2) amplification is seen...

8

23

76

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

#ColorectalCancerAwarenessMonth ✳️ Management of patients of early stage colon cancer have been evolving into precision approach step by step ! In this tweetorial, will overview adjuvant therapy approaches for patients with colon cancer❗️ @OncoAlert @manjuggm @CrcChange

4

28

76

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#esmo22 ✳️ Some take home CRC updates in @myESMO highly promising yet needing some discussion‼️ @OncoAlert @CrcChange @manjuggm @fireflyann Here are some my humble thoughts 👇

3

23

74

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

👉BRAF mutations are now actionable in CRC. 👉However, it is critical to define distinct molecular subgroups of BRAF mutants. 👉In this work, we developed an algorithmic precision approach for the management of mCRC with a BRAF alterations @ASCO @ASCO_pubs @OncoAlert

Tweet media one

Tweet media two

4

28

72

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

1 year

✳️Our work regarding the role of immunotherapy for neoadjuvant treatment of MSI-H Gastrointestinal Cancer is now out ‼️ @OncoAlert @UPMCHillmanCC @AnwaarSaeed3 @CrcTrialsChat @manjuggm Here are some key messages 👇

Tweet card media

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing...

Immune checkpoint inhibitors have revolutionized the management of mismatch repair-deficient (MMR-D)/microsatellite instability-high (MSI-H) gastrointestinal cancers, particularly colorectal cancer....

1

21

74

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

9 months

✳️Made it to the airport for #GI24 @ASCO ‼️ ✳️ Got over 20 meetings in next two days but truly excited for it ❗️ (hoping to survive ☺️) ✳️Looking forward to catching up and connecting with friends and colleagues ‼️

Tweet media one

5

2

72

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

ASCO #GI23 CRC highlights -2 ✳️Sunlight trial phase III RCT is positive, confirming superiority of Lonsurf Avastin compared to Lonsurf monotherapy with improved OS and PFS❗️Bevacizumab should be added to lonsurf if used (when no actionable gene) period ❗️ @OncoAlert

Tweet media one

Tweet media two

1

17

71

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

1 year

✳️Our article discussing the role of immunotherapy for patients with MSS CRC with TMB high is now out ‼️ Here are some key messages 👇 @UPMCHillmanCC @OncoAlert @CrcTrialsChat @manjuggm @CharanVegivinti @AnwaarSaeed3

Tweet media one

3

25

70

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

ASCO #GI23 CRC highlights ✳️Really excited to see new generation of immune checkpoint inhibitors showing good activity in CRC ❗️ #Botensilimab #balstilimab ✳️While we need to more data, I am hopeful we will break immune cold nature of MSS CRC in near future ❗️ @OncoAlert

Tweet media one

Tweet media two

Tweet media three

1

16

70

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

Some interesting findings of Galaxy trials from my view : ✳️Cumulative clearance rate was high but then even 19% of those who cleared #ctDNA , had disease recurrence in 18 months ‼️ ✳️This means ctDNA clearance does not always mean a cure, rather just undetectable ❗️ @OncoAlert

Tweet media one

Tweet media two

4

22

67

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️NAPOLI-3 trial is positive and improves both OS and PFS compared to gemcitabine abraxane ❗️ ✳️However OS is similar to FOLFIRINOX (11.1 vs 11.1). ❗️ ✳️High rates of diarrhea is not surprising in investigational arm❗️ @OncoAlert

Tweet media one

Tweet media two

Tweet media three

1

15

65

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

6 months

✳️While concluding the #ColorectalCancerAwarenessMonth just received this amazing news !! ✳️Our paper on KRAS targeting for patients with CRC is now accepted for a publication in @JCOOP_ASCO ‼️ ✳️We discussed the recent progress and elaborated future therapeutic opportunities

Tweet media one

8

7

67

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

11 months

✳️I was thrilled to join @WhiteHouse Cancer Moonshot Colorectal Cancer Listening Session ❗️ ✳️I am more hopeful than ever that clinical trials and trial opening process can be revolutionized to improve inclusivity and accessibility particularly for patients with young onset

Tweet media one

Tweet media two

8

10

63

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

7 months

Some goodbyes are really hard in oncology… Some last talks that I wish I never had to do, are really challenging … Joining to the journey of my patients has been a true privilege ‼️ Yet, the last hug, the last words, and the last goodbye can be overwhelming…

2

5

64

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

9 months

✳️Although my research is purely focused colorectal cancer, I was delighted to work on this pancreatic cancer project with Dr @SalemGIOncDoc @elrefai_sara ‼️ ✳️Also being mentee of an international PDAC expert @EileenMOReilly was helpful to put this together ☺️ ✳️Some important

Tweet media one

@ASCO

ASCO

9 months

. @IbrahimSahinMD1 , @elrefai_sara & @SalemGIOncDoc discuss the importance of germline #GeneticTesting in all pts w/ PDAC, regardless of stage of disease & family history at the time of diagnosis: #gicsm #ASCODailyNews

Tweet media one

0

5

18

4

13

62

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

HER2 targeting for patients with CRC continues to evolve ‼️ ✳️With recent data on the Mountaineer trial it is time to overview #HER2 targeting for pts with CRC @oncoalert @manjuggm @fireflyann @CrcChange Some important points to consider👇

2

21

60

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

1 year

Was great to be back to my medical school #Hacettepe University to meet with young and brilliant minds in person and chat about cancer science and academia❗️ ✳️Exciting to see the future of science is bright with many young and dedicated physicians/scientists ‼️

Tweet media one

0

3

60

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

10 months

✳️Ready for ASCO #GI24 ‼️ @ASCO ✳️Can’t wait to catch up with my mentors and colleagues from academia and pharma and brainstorm for concept development to move the field forward for patients with CRC, while learning about updates‼️ ✳️Also excited that my mentees and I will be

Tweet media one

2

1

61

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

8 months

✳️Alarming numbers for Early Onset Colorectal Cancer seen last year statistics (representing 2020) continues to be noted in this year statistics (representing 2021 data) while incidence in overall population continues to go down (effective screening for those >45)‼️ ✳️CRC, once

Tweet media one

Tweet media two

Tweet media three

Tweet media four

3

26

61

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

The last day at work ✅ As a son of farmer family from small town Turkey, it was not a straight path and it won’t be❗️ I have chased my dreams/goals;will continue to do so and MLK’s inspiring words will continue to ring in my ears during this journey❗️

1

8

56

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ColorectalCancerAwarenessMonth 1️⃣ ✳️I would like to dedicate my second tweetorial for KRAS targeting❗️ ✳️KRAS oncogene, long considered undruggable, now potentially actionable though there are hurdles we need to overcome for non-G12C👇❗️ @oncoalert @ @colontown @TheColonClub

4

14

57

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

Our paper is out ‼️ ✳️The study that we investigated prognostic markers of MSI-H CRC in a cohort of over 1100 patients is now published in the @OncJournal . @CrcChange @OncoAlert @ElaineTanMD ✳️We identified age and BRAF mutations as prognostic markers ❗️

Tweet card media

BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-defic...

Mismatch repair deficiency (MMR-D) or microsatellite instability-high (MSI-high) disease is prevalent in populations of patients with metastatic colorectal

academic.oup.com

4

14

52

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#Day1 @UPMCHillmanCC ✳️So excited to start to this new journey ❗️ ✳️ Look forward to continue to contribute to the science to advance management of colorectal cancer for our patients ‼️ @teekayowo @OncoAlert @CrcChange @manjuggm #Sciencematters ❗️

Tweet media one

Tweet media two

4

5

54

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

Pancreatic cancer stroma remains a dilemma for physicians scientist! In our study with @EileenMOReilly and Gokce Askan we identified that patients with dense stroma had lower cumulative local recurrence compared to pts with loose stroma! 👉 @OncoAlert

Tweet media one

4

15

51

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

Made it home with this amazing news❗️ ✳️Humbled to be the first author of the very first paper of CIRCULATE-US❗️ We discussed the rationale, study design and key tips of pts enrollment ❗️ @oncoalert @EileenMOReilly Was amazing to work Dr Dasari and Dr Lie ❗️True Honor❗️

Tweet media one

3

8

51

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

The truck is now loaded for the new journey to Pittsburgh ‼️ #academiclife #pursueTheScience #chaseyourdreams

Tweet media one

2

2

51

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

ASCO #GI23 @UPMCHillmanCC GI Oncology crew on their way to ASCO #GI23 ☺️ @AnwaarSaeed3 @JanieYZhang

Tweet media one

2

4

51

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️This concerning trend warrants urgent intervention and more science to better understand the biological underpinnings of the #CRC epidemic in the US‼️ @CrcChange @CrcTrialsChat @FightCRC @manjuggm @TheColonClub @TheColonClub

3

11

51

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

1 year

A 6-2 📌TNT is not recommended for pts with MSI-H #RectalCancer !! 📌 Pts with MSI-H LARC may have dz progression with induction or consolidation chemo, not common in pts with MSS LARC. 📌NCCN now endorses ICI tx for MSI-H pts with intention for organ preservation #CRCTrialsChat

1

16

50

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

A @nature paper suggests B-Hyroxybutyrate suppresses CRC and hereby ketogenic diet can be also considered for CRC treatment❗️ ✳️The study is intriguing, yet many important points need discussion before concluding sugar fuels cancer👇 @OncoAlert @CrcChange

β-Hydroxybutyrate suppresses colorectal cancer

Nature - The growth of colorectal cancer is reduced by ketogenic diet consumption, the properties of which are mediated by the ketone body β-hydroxybutyrate.

1

12

49

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️Completed my last clinic, and I have say it has been very emotional last few weeks and it was not easy to say good bye to my patients‼️ ✳️Being oncologist is a true privilege and it was true honor being part of journey of my patients❗️They will remain in my prayers…

1

5

47

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

10 months

✳️ Colorectal is increasingly being a disease of younger population and we need more creative clinical trials ❗️ ✳️ Here is the major discrepancy : Only ~6% patients living with CRC are enrolled in a therapeutic clinical trials and yet most of the precision medicine trials in

Tweet media one

2

19

47

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ASCO22 ✳️The standard of care for MMR-D rectal cancer is changing/changed❗️ ✳️We should do all we can to avoid surgery for patients with MMR-D rectal cancer ❗️ ✳️Although data is early and it is highly promising enough to move forward ‼️ @asco @OncoAlert @MoffittNews 👇

Tweet media one

Tweet media two

Tweet media three

Tweet media four

3

16

47

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

Immune checkpoint inhibitor therapy doesn’t only prolong survival outcomes but also improves quality of life of MMR-D/MSI-H colorectal cancer patients! @OncoAlert @MoffittNews

Tweet media one

1

12

47

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

Wanted start my day with a clarification as I am getting messages from my patients due to incomplete media reporting‼️ ✳️Dostarlimab was studied only Mismatch Repair Deficient Rectal Cancer seen only 5-10% only of pts‼️ @OncoAlert @colontown @CrcChange

3

17

49

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

1 year

Excited and thrilled to co-chair #Pittsburgh First Annual Gastrointestinal Cancer Symposium ❗️ 👉With outstanding list of speakers and exciting topics, we will overview recent progress and provide a projection to the future of GI Oncology @OncoAlert @AnwaarSaeed3 @AmerZureikatMD

Tweet media one

Tweet media two

1

11

48

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

10 months

✳️It was first but also very memorable first in-person experience with #IGICC in Turkey with several GI Oncology giants from Europe and the US including Dr Van Cutsem, Dr Marc Peeter, Dr Philip Philip and Dr Ahmed Kaseb and several experts from the field @AnwaarSaeed3

Tweet media one

Tweet media two

Tweet media three

0

7

47

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️Was amazing to meet #KRASkickers team today ‼️ ✳️We agreed on continuing to work together to deliver cutting edge science to our patients ❗️ Thank you @TerriConneran ❗️ @JanieYZhang

Tweet media one

3

2

46

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

8 months

✳️So proud of my mentees who made it to all the way to SF to present their work ‼️ #GI24 They will be presenting their work in CRC from young onset CRC to molecular subgroups of CRC‼️ ✳️Consider stopping by their posters‼️ @ASCO @UPMCHillmanCC @MasoodPashaSyed

Tweet media one

Tweet media two

2

8

47

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

So excited that our paper accepted for publication by @JCOOP_ASCO @ASCO ✳️Stay tuned for this highly exciting article that we discussed HER2 targeting approaches for patients with CRC‼️ @OncoAlert #PrecisionMedicine #MedTwitter

Tweet media one

2

5

45

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

7 months

✳️Starting to #colorectalcancerawareness with a great news ❗️ Our Editorial with @manjuggm @ARosen380 , Dr Seth Felder and Dr Jessica Frakes discussing the most recent updates on management of locally advanced rectal cancer and the PROSPECT trial is accepted for a publication ‼️

Tweet media one

2

5

45

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

Our ASCO Educational Book Chapter is out!l Happy to see that in the first day of #ASCO22 ✳️We have discussed challenges of immunotherapy for MSS CRC and existing opportunities to move the field forward❗️ @OncoAlert @ASCO @manjuggm @fireflyann Here are some take home points

3

6

45

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

CIRCULATE-US is now active and recruiting❗️ I would like to increase awareness for this highly important study as it may impact future practice (also my duty as a study champion 😊) ‼️ @oncoalert @CrcChange @fireflyann @manjuggm #medtwitter #ctDNA Here is why 👇

2

15

43

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

11 months

✳️Was exciting to join #Alliance GI committee meeting in-person and discuss and stay up to date on ongoing studies in the field and also create opportunities for collaboration to move the field forward ! Always true pleasure and honor catching up with my life long mentor

Tweet media one

0

2

44

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

8 months

✳️So excited and ready to make it home after a busy but also quite productive meeting ❗️Was a memorable one indeed ‼️ #GI24 @ASCO ✳️Safe travels back to home everyone ‼️

Tweet media one

1

1

43

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

Tried to carve T cell and Cancer cell interaction on my pumpkin 🎃❗️Well, would not say it was so successful even with extra help of antibody cucumbers 😄

Tweet media one

Tweet media two

2

6

42

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

10 months

Entering Thanksgiving with my amazing team by rounding on the floor☺️ ✳️Happy Thanksgiving Everyone ‼️

Tweet media one

0

0

43

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

#ColorectalCancerAwarenessMonth When determining therapeutic options for advanced stage CRC, one of the most important step is to define oligometastatic disease particularly for patients with young onset disease❗️ @OncoAlert @CrcChange @DenboJw Here is why 👇

3

14

41

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

8 months

✳️The AZUR-1 trial, testing the efficacy of dostarlimab for patients with MMR-D/MSI-H rectal cancer, is now open and enrolling at @UPMCHillmanCC ‼️ ✳️This trial will serve to patients in with #lynch syndrome and rectal cancer or those with sporadic MMR-D Rectal Cancer‼️ Please

1

12

42

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

#ColorectalCancerAwarenessMonth ✳️ Science have revealed many therapeutic opportunities for the management of patients with CRC❗️ ✳️ This tweetorial is meant to create awareness precision treatments for patients with advanced stage CRC ❗️ @OncoAlert @CrcChange @TheColonClub

3

18

40

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

Heading to Chicago for my first in person @ALLIANCE_org Spring GI Committee Meeting ‼️Very excited to see my colleagues in person after a while❗️

Tweet media one

1

1

41

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

#GI22 @ASCO @OncoAlert ✳️ A Highly promising KRAS 12C inhibitor is on its way‼️ #Adagrasib ✳️Even though early result, 50% of PR is quite impressive ❗️ Congrats Dr @GIcancerDoc ❗️ 👉We need more RAS inhibitors for other RAS mutations for GI cancers…

Tweet media one

Tweet media two

0

7

40

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️Was amazing to see with my twitter friends @ARosen380 @CancerInsider in person ☺️, such a privilege ❗️ ✳️Was so happy to hear my twitter contents contribute to awareness on colorectal cancer ❗️ ✳️Look forward to working closely and help our community ❗️

Tweet media one

1

0

40

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

5 years

It was delightful to finish the long day by listening the pearls of targeting DDR pathway from my life long mentor Dr. @EileenMOReilly and Dr. Bekaii-Saab @GIcancerDoc !

Tweet media one

0

4

40

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

Exciting studies in CRC #GI22 @ASCO 👉CtDNA 📈 remains single most powerful prognostic factor for recurrence . #CIRCULATE Japan 👉patients who clear ctDNA after chemo do well while persistent ctDNA predicts poor outcomes❗️ 👉 Conversion ➖ to ➕ also associated with worse DFS.

@ASCO

ASCO

3 years

🚨 The #GI22 abstracts are now available! Read the latest practice-changing findings in GI cancer treatment, research, and care ➡️ #gicsm #gionc

Tweet media one

0

23

45

1

14

38

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

1 year

✳️ KRAS G12C is now among actionable alterations ❗️ In this #ASCODailyNews article Dr. @NiuSanford @jonathanloree and I discussed what makes G12C so unique for drug development compared to others ❗️ @OncoAlert @ASCO Here is that exciting article :

Breaking the Code: Emerging Strategies for KRAS Inhibition

What makes KRASG12C potentially targetable versus other KRAS mutations? Because of their unique molecular environment, strategies targeting KRASG12C mutations vary by cancer type, and there are...

dailynews.ascopubs.org

3

12

39

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

Immune checkpoint inhibitors have led to paradigm shift in MMR-D CRC management. In our multinational study we investigated predictor of IO therapy response : @MoffittNews @OncJournal @OncoAlert

Tweet media one

2

13

40

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

On the board for #ASCO22 ‼️ Look forward to meeting with colleagues and engage to academic progress and discussion‼️ @ASCO

Tweet media one

1

0

40

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ASCO22 #plenary ✳️The results of the PARADIGM trial was somewhat expected and was consistent with FIRE-3 trial ‼️ ✳️Lack of improvement in PFS but improvement in OS perhaps driven by clonal selection process ‼️ @OncoAlert @ASCO @MoffittNews

Tweet media one

Tweet media two

Tweet media three

Tweet media four

1

11

37

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

#GI22 ✳️Heading to San Francisco ❗️ Thank you @ASCO Very excited to meet with my colleagues and mentors❗️

Tweet media one

2

1

39

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ASCO22 ✳️I would like to do deep dive post ASCO analysis for some important CRC studies with cross comparison ‼️ ✳️I think some studies did not get enough attention and also there is value elaborate more on future opportunities ❗️ @OncoAlert @manjuggm @CrcChange

1

13

39

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

7 months

✳️Our first presentation for #ColorectalCancerAwarenessMonth is now out ‼️ ✳️This is dedicated to early onset CRC which personally affected my family member and made me to start my journey in Oncology‼️ Here are some take home points 👇 @Sameh_VuMedi @VuMediHemOnc @VuMedi

1

14

39

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

8 months

✳️Svea, a medical student from @PittTweet will be presenting incidences of MAPK and mTOR pathway alterations seen in HER2 amplified CRC which is unique subgroup ‼️ #GI24 @ASCO ✳️Interesting findings indeed ❗️So proud of her ‼️

Tweet media one

Tweet media two

0

5

38

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

4 years

The new chapter is about to begin!! So excited to contribute academic efforts at @MoffittNews to make a difference in cancer patients life ! #ScienceMatters #Precisiononcology

Tweet media one

1

1

36

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️It was interesting to read this article but I do think the title of this manuscript and conclusion is not reflecting each other very well ‼️ @OncoAlert @manjuggm @CrcChange @fireflyann Here is why 👇

Tweet media one

4

8

38

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

👉Hard to believe that there are health insurances rejecting molecular profiling for cancer patients❗️❗️ 👉While we advocate precision medicine to capture each single opportunity to make a chance in cancer patients life, looks like facts are not facing each other‼️ @OncoAlert

1

6

38

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

✳️Nivo&Ipi combination is moving to first line for MSI-H CRC as expected and we need a randomized trial❗️ ✳️Interestingly, unlike KYN 177, RAS mutant MSI-H CRC pts seems like doing better than RAS wild type with Nivo&Ipi‼️ @CrcChange @ASCO_pubs @OncoAlert

Tweet card media

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair...

PURPOSENivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient...

1

13

35

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

Was such a great pleasure to meeting @MyriamChalabi @aparna1024 in person ❗️ ✳️The progressive and bold move of Dr @MyriamChalabi to bring IOs to neoadjuvant space - years ago - should be a model for our oncology community❗️ ✳️Look forward to follow footsteps of Dr @aparna1024 ❗️

Tweet media one

0

1

38

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ASCO22 So glad to be back to in person after a long break @ASCO ‼️ ✳️Looking forward to reconnect with colleagues and mentors in person and discuss progresses in science more interactively ‼️

Tweet media one

0

1

36

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

An important question is how to optimize BRAF targeting for patients with mCRC❗️ In fact, prescise approach for BRAF may impact outcomes❗️ ✳️Therefore, it’s important define BRAF alterations to determine right therapy @oncoalert @CrcChange @fireflyann @manjuggm Here is why👇

3

18

34

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

✳️Targeting therapy for BRAF V600E mutant CRC moving forward‼️ ✳️The findings of the ANCHOR trial are promising but also suggests BRAF doublets/triplets may need to be combined with chemotherapy in the first line tx❗️ @ASCOPost @CrcChange @OncoAlert

Tweet card media

BRAF-Mutant Colorectal Cancer: Latest Findings for Targeted Treatment

The phase II ANCHOR CRC study, the largest prospective study of BRAF inhibitor–based therapy as first-line treatment of metastatic colorectal cancer, has met its primary endpoint, with 47.8% of...

1

15

36

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

Highlands of Turkey! Trabzon and Sumela Monastery ‼️

Tweet media one

Tweet media two

Tweet media three

Tweet media four

1

2

37

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

3 years

#ASCO21 Excited for @asco 2021 !! #Early CRC updates @OncoAlert 👉Pembrolizumab doubled mPFS (16.5 vs 8.2 ms)-KYN177 ! OS favored Pembro yet not significant due to crossover! 👉HER2 targeting with Trastuzumab Deruxtecan /T-Dxd resulted in 43% ORR in pts with prior HER2 tx!

1

11

36

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ASCO22 ✳️Excited CRC oral abstracts tomorrow ‼️ ✳️Will be going over overall CRC updates of ASCO tomorrow with a tweetorial, stay Tuned ‼️ @OncoAlert @ASCO @CrcChange

1

2

35

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

✳️Happy to see a concept I presented in CRC Task Force year ago for pts with BRAF V600E MSI-H CRC in refractory setting is now being brought to first line by @pfizer ‼️ Happy to see this concept moved forward (without my involvement) as this is highly important for our patients

Tweet media one

4

6

36

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

5 years

I am very humbled with this award ! A special thanks to my mentors @EileenMOReilly @BasselElRayesMD and Christina Wu. And of course thank you @ASCO for this honor and recognition! @WinshipAtEmory

Tweet media one

1

0

36

@IbrahimSahinMD1

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

2 years

#ASCO22 ✳️Would like to do my 3rd post #ASCO22 analysis on neoadjuvant therapy for patients with colon cancer ‼️ ✳️Beside, the OPTICAL trial, there is also growing interest for neoadjuvant approaches for colon CA, are we there yet? opportunities and challenges ? @OncoAlert 👇

1

15

34